Page 3 - Intramural Program News Today

Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper a...

Risk of miscarriage in women with chronic diseases in Norway: A registry linkage study Maria C. Magnus , Roles Investigation, Methodology, Writing – review & editing Affiliations Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway, Department of Clinical Science, University of Bergen, Bergen, Norway, Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway ⨯ Knut-Arne Wensaas, Affiliation R...

Why do we lose our sense smell/taste with COVID? The angiotensin-converting enzyme 2 (ACE2) enzyme attached to the membranes of cells is the entry point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They are abundantly found all over the body and most prominently in the lungs and nose. This coincides with initial symptoms exhibiting loss of smell and respiratory problems. Another early symptom of SARS-CoV-2 infection is loss of taste, although the mechanism of why this happe...

Arctic Journal  One youth leader at a time Without question, life became a little more challenging after March 2020. But that didn’t stop more than 200 youth leaders across Nunavut from making a difference through recreation and sport in their communities. In the last seven years, more than 750 youth leaders have participated in Recreation & Parks Association of Nunavut (RPAN) initiatives, combining training, certification, leadership and employment (seasonal and casual) to deliver quality...

1Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, Maryland 2Center for Communicable Disease Dynamics, Department of Epidemiology, Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 3Weill Cornell Medical College, New York, New York JAMA. 2021;325(3):219-220. doi:10.1001/jama.2020.25053